ArticleClinical and experimental medicine2023

An HPK1 inhibitor enhanced the tumour response to anti-PD-1 immunotherapy in non-Hodgkin's lymphoma.

Lin Yang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.